Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
venerdì, ottobre 09
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Vor Biopharma Inc
VOR
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$19.79
0.66
3.42%
Ult. Agg.: Oct 9, 3:34 PM
$19.67
0.54
2.82%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Vor Biopharma Financials
Vor Biopharma (VOR) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
UPDATE: Vor Biopharma Q2 Adj. EPS $(0.80) Misses $(0.70) Estimate
Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.70) by 14.29 percent. This is a 98.17 percent increase over losses of $(43.80) per share from
Benzinga Newsdesk
PRO
Vor Biopharma Q2 EPS $(1.16) Misses $(0.70) Estimate
Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(1.16) per share which missed the analyst consensus estimate of $(0.70) by 65.71 percent. This is a 99.54 percent increase over losses of $(251.24) per share from
Benzinga Newsdesk
PRO
Vor Biopharma Q1 Adj. EPS $(0.73) Beats $(0.78) Estimate
Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.78) by 6.41 percent. This is a 85.96 percent increase over losses of $(5.20) per share from the
Benzinga Newsdesk
PRO
Vor Biopharma Q4 Adj. EPS $(1.63) Beats $(1.64) Estimate
Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(1.63) per share which beat the analyst consensus estimate of $(1.64) by 0.61 percent. This is a 81.48 percent increase over losses of $(8.80) per share from the
Benzinga Newsdesk
PRO
UPDATE: Vor Biopharma Q3 Adj. EPS $(3.33) Misses $(3.25) Estimate
Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(3.33) per share which missed the analyst consensus estimate of $(3.25) by 2.37 percent. This is a 58.39 percent increase over losses of $(8.00) per share from the
Benzinga Newsdesk
PRO
Vor Biopharma Q3 EPS $(121.63) May Not Compare To $(3.32) Estimate
Benzinga Newsdesk
